Immune Checkpoint Inhibitor
Oncologists play key role in diagnosing immune checkpoint inhibitor-induced myocarditis
Incidence of immune checkpoint inhibitor-induced myocarditis may increase as more patients receive immunotherapy. In this special report, Healio | HemOnc Today highlights how a multidisciplinary approach can reduce mortality through early recognition and prompt intervention.
Tumor-treating fields extend OS in metastatic NSCLC
CHICAGO — The addition of tumor-treating fields to second-line therapy prolonged survival for patients with metastatic non-small cell lung cancer whose disease progressed on or after platinum therapy, according to results presented at ASCO Annual Meeting.
Tumor mutational burden may be linked to immunotherapy response in advanced cancers
Cancers with high vs. low tumor mutational burden appeared significantly associated with improved clinical outcomes among patients treated with immune checkpoint inhibitors, according to data published in JAMA Network Open.
Specificity of definition of ICI-related myocarditis improved after minor change
A modified version of the International Cardio-Oncology Society definition of immune checkpoint inhibitor-associated myocarditis may improve its predictive value, researchers reported.
Melanoma subtype influences immune-related adverse events in ICI therapy
Cutaneous immune-related adverse events are highly dependent on melanoma subtype among immune checkpoint inhibitor therapy recipients, according to a study.
Pembrolizumab regimen extends survival in advanced gastric, gastroesophageal cancer
The addition of pembrolizumab to chemotherapy significantly extended survival among patients with advanced HER2-negative gastric or gastroesophageal junction cancer, according to results of the phase 3 KEYNOTE-859 study.
Survival improved among immune checkpoint inhibitor recipients with cirAEs
Cutaneous immune-related adverse events are associated with increased survival rates among immune checkpoint inhibitor recipients, particularly in patients with melanoma, according to a study.
BMI linked to safety of checkpoint inhibitors among patients with advanced cancer
High BMI appeared associated with increased risk for any-grade immune-related adverse events among a cohort of patients with advanced cancer undergoing treatment with immune checkpoint inhibitors.
Survival gains with checkpoint inhibitors differ ‘drastically’ between age groups in NSCLC
Despite significantly extending survival for younger adults with advanced non-small cell lung cancer, immune checkpoint inhibitors have conferred only modest OS gains over time among patients aged older than 75 years, study results showed.
Addition of tumor treating fields to standard therapy extends OS in advanced lung cancer
The addition of tumor treating fields to standard therapies significantly improved OS for certain patients with non-small cell lung cancer, according to the therapy’s manufacturer.